drugset
drugset / Trial / NCT00854009

Study Evaluating Single Doses of BLI-489 in Healthy Japanese Male Subjects

NCT00854009 ↗

Phase 1 Completed 40 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of single doses of BLI-489 administered intravenously in healthy Japanese male subjects, and how the drug is absorbed and eliminated.

Timeline

Start
2009-02-20
Primary completion
2009-04-01
Completion
2009-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BLI-489 Small molecule — Intravenous

Indications

No indication recorded.